<DOC>
	<DOCNO>NCT00001007</DOCNO>
	<brief_summary>To determine intravenous ( IV ) oral zidovudine ( AZT ) safely give child age 1 day 3 month bear mother HIV infection . Also determine correct dose AZT young child . Of total 908 pediatric AIDS case , 78 percent acquire HIV infection mother HIV infection high risk acquisition HIV , number case child expect increase next several year . AZT therapy may effective alter course disease decrease high mortality child . It also possible early intervention AZT may prevent establishment HIV contract , , birth .</brief_summary>
	<brief_title>A Study Zidovudine Infants Exposed HIV Before Soon After Birth</brief_title>
	<detailed_description>Of total 908 pediatric AIDS case , 78 percent acquire HIV infection mother HIV infection high risk acquisition HIV , number case child expect increase next several year . AZT therapy may effective alter course disease decrease high mortality child . It also possible early intervention AZT may prevent establishment HIV contract , , birth . The child enter study receive oral IV AZT . The first 6 child receive 2 IV dose 2 oral dos 2-week period , 4 week continuous oral dosing ( 4 dos per day ) . The remain 12 child receive 1 IV dose 1 oral dose follow 6 week oral AZT ( 4 dos per day ) second IV dose end study . Each child care specialist pediatrics physical examination laboratory test start AZT 6 time take AZT make sure drug toxic effect child . A single cerebrospinal fluid ( CSF ) sample take last 12 child enter study , level AZT reach brain measure . The child return hospital clinic 4 week end therapy make sure delay toxic effect .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Infant gestation period must = &gt; 36 week birthweight must = &gt; 2000 gram . Active infection must present time entry study although HIV culture P24 serum antigen determination must obtain prior study entry . The child must life expectancy great 3 month . Parents guardian must available give informed consent . Prior Medication : Allowed casebycase basis : Some essential supportive therapy include antibiotic . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Any following laboratory finding within 2 week study entry . A total bilirubin &gt; 2 time ageadjusted upper limit normal . Liver transaminase value &gt; 3 x upper limit normal . Serum creatinine &gt; 1.5 x upper limit normal . Total granulocyte count &lt; 1500 cells/mm3 . Hemoglobin &lt; 10 g/dl hemoglobinopathy . A urine toxicology screen positive drug chemical . Infants must hemoglobinopathy active infection entry . Prior Medication : Excluded within 2 month study entry : Antiretroviral agent . Excluded within 4 week study entry : Immunomodulating agent include steroid , interferon , isoprinosine , interleukin . Immunoglobulin . Excluded within 2 week study entry : Any experimental therapy , drug cause prolong neutropenia significant nephrotoxicity , rifampin / rifampin derivative . Some essential supportive therapy include antibiotic may infrequent transient effect . These drug consider casebycase basis . Prior Treatment : Excluded within 2 week study entry : Red blood cell whole blood transfusion . Excluded within 4 week study entry : Lymphocyte transfusion immune reconstitution . Infants may enter study first 2 week life mother receive methadone therapy last trimester pregnancy use know illicit drug . A maternal urine toxicology screen may optionally perform prior entry child , child whose mother screen positive drug chemical may enrol within 2 week positive screen .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>January 2003</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>Infant , Newborn , Diseases</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>